{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T10:56:30Z","timestamp":1793876190052,"version":"4.7.0"},"reference-count":25,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dom-pubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To evaluate the efficacy and safety of once\u2010weekly (QW) efpeglenatide in people with type 2 diabetes (T2D) suboptimally controlled with oral glucose\u2010lowering drugs and\/or basal insulin (BI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods<\/jats:title>\n                    <jats:p>Three phase 3, multicentre, randomized controlled trials compared the efficacy and safety of QW efpeglenatide versus dulaglutide when added to metformin (AMPLITUDE\u2010D), efpeglenatide versus placebo when added to BI \u00b1 oral glucose\u2010lowering drugs (AMPLITUDE\u2010L) or metformin \u00b1 sulphonylurea (AMPLITUDE\u2010S). All trials were terminated early by the sponsor because of funding rather than safety or efficacy concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In AMPLITUDE\u2010D, non\u2010inferiority of efpeglenatide to dulaglutide 1.5\u2009mg was shown in HbA1c reduction from baseline to week 56,\u00a0least squares mean treatment difference (95% CI): 4\u2009mg, \u22120.03% (\u22120.20%, 0.14%)\/\u22120.35\u2009mmol\/mol (\u22122.20, 1.49); 6\u2009mg, \u22120.08% (\u22120.25%, 0.09%)\/\u22120.90\u2009mmol\/mol (\u22122.76, 0.96). The reductions in body weight (approximately 3\u2009kg) from baseline to week 56 were similar across all treatment groups. In AMPLITUDE\u2010L and AMPLITUDE\u2010S, numerically greater reduction in HbA1c and body weight were observed at all doses of efpeglenatide than placebo. American Diabetes Association level 2 hypoglycaemia (&lt;\u200954\u2009mg\/dL [&lt;\u20093.0\u2009mmol\/L]) was reported in few participants across all treatment groups (AMPLITUDE\u2010D, \u2264\u20091%; AMPLITUDE\u2010L, \u2264\u200910%; and AMPLITUDE\u2010S, \u2264\u20094%). The adverse events profile was consistent with other glucagon\u2010like peptide\u20101 receptor agonists (GLP\u20101 RAs); gastrointestinal adverse events were most frequent in all three studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In people with T2D suboptimally controlled with oral glucose\u2010lowering drugs and\/or BI, QW efpeglenatide was non\u2010inferior to dulaglutide in terms of HbA1c reduction and showed numerically greater improvements than placebo in glycaemic control and body weight, with safety consistent with the GLP\u20101 RA class.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/dom.15079","type":"journal-article","created":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T05:44:39Z","timestamp":1680587079000},"page":"2084-2095","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy and safety of\n                    <scp>once\u2010weekly<\/scp>\n                    efpeglenatide in people with suboptimally controlled type 2 diabetes: The\n                    <scp>AMPLITUDE\u2010D<\/scp>\n                    ,\n                    <scp>AMPLITUDE\u2010L<\/scp>\n                    and\n                    <scp>AMPLITUDE\u2010S<\/scp>\n                    randomized controlled trials"],"prefix":"10.1111","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7706-4585","authenticated-orcid":false,"given":"Vanita R.","family":"Aroda","sequence":"first","affiliation":[{"name":"Brigham and Women's Hospital, Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9486-1255","authenticated-orcid":false,"given":"Juan Pablo","family":"Frias","sequence":"additional","affiliation":[{"name":"Velocity Clinical Research  Los Angeles California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1305-1598","authenticated-orcid":false,"given":"Linong","family":"Ji","sequence":"additional","affiliation":[{"name":"Peking University People's Hospital  Beijing China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Niemoeller","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"My\u2010Li\u00ean","family":"Nguy\u00ean\u2010Pascal","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8348-4412","authenticated-orcid":false,"given":"Karl","family":"Denkel","sequence":"additional","affiliation":[{"name":"Sanofi  Frankfurt Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Espinasse","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly\u2010Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hailing","family":"Guo","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3385-2077","authenticated-orcid":false,"given":"SeungJae","family":"Baek","sequence":"additional","affiliation":[{"name":"Hanmi Pharmaceutical  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JaeDuk","family":"Choi","sequence":"additional","affiliation":[{"name":"Hanmi Pharmaceutical  Seoul South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7006-7401","authenticated-orcid":false,"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center  Dallas Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,4,26]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S009"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.2337\/dci22-0034"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc13-2759"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14020"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc18-2648"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108269"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603827"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31149-3"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00394"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.08.088"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2012.140"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-s231"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.00178"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-2656"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc22-S006"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-1625"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.12849"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/dmrr.3070"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-022-01284-2"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2012.03.001"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2014.01.012"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/dom.15079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T04:10:59Z","timestamp":1761883859000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/dom.15079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,26]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1111\/dom.15079"],"URL":"https:\/\/doi.org\/10.1111\/dom.15079","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/DOM.15079\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15079\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15079\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15079\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15079\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/DOM.15079\/v2\/decision1","asserted-by":"object"}]},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,26]]},"assertion":[{"value":"2023-01-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}